Literature DB >> 7521171

Interactions of alpha-1-antichymotrypsin, alpha-1-proteinase inhibitor, and alpha-2-macroglobulin with the fungal enzyme, seaprose.

E Korzus1, M Luisetti, J Travis.   

Abstract

The Semi-alkaline proteinase (Seaprose) from Aspergillus melleus has been tested for its ability to either inactivate or form complexes with three human plasma proteinase inhibitors, alpha-2-macroglobulin, alpha-1-antichymotrypsin and alpha-1-proteinase inhibitor. alpha-2-Macroglobulin was found to inhibit Seaprose, with two mol of enzyme being complexed per mol of inhibitor. However, alpha-1-proteinase inhibitor was rapidly inactivated by the fungal enzyme as a result of cleavage of the inhibitor, primarily at the P1-P'1 reactive site. Curiously, alpha-1-antichymotrypsin was found to form complexes with Seaprose and also be inactivated by this inhibitor. Apparently, the enzyme can recognize two sites within the reactive site loop of the inhibitor, one at the P4-P'5 position, resulting in inactivation, and one presumably at the P1-P'1 reactive site which results in complex formation. The fact that Seaprose can so rapidly inactivate alpha-1-proteinase inhibitor, the primary regulator of neutrophil elastase, indicates that Seaprose would be a rather poor choice for therapy in individuals with bronchial mucus hypersecretion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7521171     DOI: 10.1515/bchm3.1994.375.5.335

Source DB:  PubMed          Journal:  Biol Chem Hoppe Seyler        ISSN: 0177-3593


  2 in total

1.  Isolation and properties of stachyrase A, a chymotrypsin-like serine proteinase from Stachybotrys chartarum.

Authors:  Tomasz Kordula; Agnieszka Banbula; Jeremy Macomson; James Travis
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

2.  Multiplex quantification of C-terminal alpha-1-antitrypsin peptides provides a novel approach for characterizing systemic inflammation.

Authors:  Arite Bigalke; Christoph Sponholz; Claudia Schnabel; Michael Bauer; Michael Kiehntopf
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.